KEWAUNEE SCIENTIFIC CORP /DE/ financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data KEWAUNEE SCIENTIFIC CORP /DE/ files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	139	158	147	148	147	169	219	204	240	282
Cost of revenue	112	126	121	124	123	145	184	152	172	202
Gross profit	26.6	32.2	25.3	23.4	24	24.2	35.6	52.1	68.9	80.4
Research and development	1.16	1.54	1.55	1.82	1.41	0.99	1.01	0.92	0.92	0.9
Operating expenses	20.1	22.2	23.2	25.8	25.3	26.8	30.2	33.8	51.1	63.7
Operating income	6.54	9.92	2.11	-2.35	-1.32	-2.61	5.36	18.3	17.8	16.7
Interest expense	0.29	0.3	0.37	0.49	0.39	0.63	1.73	1.8	3.21	3.86
Pre-tax income	6.75	9.62	2.13	-2.87	-2.62	-2.49	4.5	13.1	14.8	13.7
Income tax	2.13	4.16	0.45	1.76	0.99	3.52	3.14	-5.94	3.2	3.27
Net income to minority interests	0.11	0.18	0.16	0.06	0.07	0.12	0.62	0.3	0.18	0.85
Net income	4.52	5.28	1.53	-4.69	-3.67	-6.13	0.74	18.8	11.4	9.62
EBITDA	9.24	12.7	4.68	0.31	1.37	0.16	8.23	21.4	22.5	23
EPS, basic	1.77	2.06	0.56	-1.70	-1.33	-2.20	0.26	6.51	3.98	3.36
EPS, diluted	1.76	2.01	0.55	-1.70	-1.33	-2.20	0.25	6.38	3.83	3.22
Shares, basic (weighted)	2.55	2.57	2.74	2.75	2.76	2.79	2.82	2.88	2.86	2.86
Shares, diluted (weighted)	2.57	2.62	2.79	2.75	2.76	2.79	2.9	2.94	2.98	2.98
Dividend per share	0.61	0.70	0.74	0.38

Balance sheet

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cash and equivalents	12.5	9.72	10.6	4.37	5.21	4.43	8.08	23.3	14.9	9.95
Receivables	29.9	32.7	33.3	28.1	32.9	41.3	46.1	45.1	62.4	58.7
Inventory	14.9	18.5	17.2	15.3	16.5	23.8	21.9	20.7	32.8	30.5
Other current assets	1.05	2.22	3.74	2.91	4.37	6.16	6.14	5.14	5.97	4.51
Total current assets	59.8	64.4	65.4	54.2	60.5	91.6	87.9	96.8	118	105
Property, plant and equipment	14	14.7	16.5	16.3	16	15.1	16.4	17.6	23.2	22.4
Lease right-of-use assets				9.31	9.28	7.57	9.17	7.45	13	10.8
Goodwill								0	12.5	12.5
Intangible assets								0	17.8	16.3
Other non-current assets	3.92	4.16	3.58	3.78	3.67	4.51	5.41	5.45	5.84	7.15
Total assets	80.9	85.1	87.2	83.9	89.4	119	119	135	195	178
Accounts payable	12	14.8	15.2	13.1	16.8	27.3	23.6	23.3	27	22.5
Accrued liabilities	2.77	3.81	1.51	4.16	4.73	4.5	4.3	6.04	9.21	8.82
Deferred revenue	5.81	1.88	1.6	2.51	3.12	3.53	4.1	4.37	6.07	4.15
Short-term debt	0.92	1.17	1.17	0	6.83	1.59	3.59	3.1	3	5
Total current liabilities	26.9	27.6	32.7	27.1	34.2	42.3	40.1	40.8	53.7	48.4
Long-term debt		1.26	0.23					0	34.7	15.1
Lease liabilities				7.78	7.86	6.18	7.14	5.43	8.8	6.29
Other non-current liabilities		0.55	0.68	0.57	0.81	0.53	0.46	0.46	0.36	0.29
Total liabilities	37.7	36.9	39.5	45.2	47.9	82.6	80.4	78.6	128	101
Total debt	2.43	1.26	0.1	0					37.7	20.1
Paid-in capital	2.7	3.01	3.13	3.36	3.81	4.48	5.06	5.41	5.64	7.02
Retained earnings	39.8	43.8	43.6	37.8	34.1	28	28.8	47.5	58.9	68.5
Treasury stock	-0.05	-0.05	-0.05	-0.05	-0.05	-0.05	-0.05	-2.05	-3.65	-3.65
Other comprehensive income	-6.32	-5.9	-6.41	-9.6	-3.58	-3.74	-3.44	-3.38	-3.8	-4.61
Shareholders' equity	43.5	47.7	47.1	38.4	41.2	35.7	37.4	54.8	64.5	74.7
Minority interests	0.37	0.46	0.6	0.29	0.25	0.49	1.08	1.45	1.79	2.09
Total equity	43.3	48.2	47.7	38.7	41.5	36.2	38.5	56.2	66.2	76.8
Total liabilities and equity	80.9	85.1	87.2	83.9	89.4	119	119	135	195	178
Shares outstanding	2.56	2.58	2.75	2.75	2.76	2.79	2.83	2.84	2.84	2.87

Cash flow statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Net income	4.62	5.46	1.69	-4.62	-3.61	-6	1.36	19.1	11.6	10.5
Depreciation and amortization	2.7	2.76	2.57	2.65	2.69	2.77	2.87	3.13	4.76	6.28
Stock-based compensation	0.2	0.36	0.2	0.25	0.63	0.73	0.89	1.03	1.44	2.13
Deferred income tax	-0.35	0.72	0.03	2.43	0.24	0.12	0.52	-11	-2.2	-0.02
Change in receivables	-2.09	-3.12	-0.66	4.83	-4.87	-8.46	-4.95	0.74	-6.74	3.3
Change in inventory	0.69	-2.87	0.46	1.88	-1.19	-7.28	1.91	1.21	3.35	2.32
Change in payables	0.69	4.61	-0.06	-2.02	4.57	11.9	-5.56	0.69	0.58	-5.15
Cash from operations	11.7	3.18	2.49	4.16	0.91	-7.89	-3.79	19.6	14.8	18.6
Capital expenditures	-2.61	-3.4	-4.21	-2.47	-2.4	-1.91	-4.15	-4.37	-2.17	-3.94
Acquisitions								0	-28.7	0
Cash from investing	-2.48	-3.4	-4.21	-2.47	-2.4	-1.91	-4.15	-4.37	-30.9	-3.94
Debt issued					0	0.38	0	0.2
Debt repaid	-0.42	-0.92	-1.18	-1.28	-0.02	0	-0.12	-0.09
Share buybacks							0	-2	-1.6	0
Dividends paid	-1.57	-1.79	-2.03	-1.04	0
Cash from financing	-2.08	-2.48	2.33	-7.46	1.98	11	14.9	-3.01	7.41	-19.3
Exchange rate effect	0.19	-0.29	-0.41	-0.18	0.02	-0.08	-0.07	-0.05	-0.07	-0.92
Net change in cash	7.28	-2.98	0.2	-5.94	0.52	1.16	6.92	12.1	-8.77	-5.55
Free cash flow	9.05	-0.21	-1.72	1.7	-1.49	-9.79	-7.94	15.2	12.6	14.7
Interest paid	0.29	0.3	0.35	0.51	0.07	0.48	1.86	1.8	3.37	3.33
Income taxes paid	2.62	2.87	2.46	0.19	-1.8	1.01	3.16	6.24	3.97	3.56

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $34.02 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	28.6%	Gross profit / revenue.
Operating margin	5.4%	Operating income / revenue.
EBITDA margin	7.7%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	4.5%	Pre-tax income / revenue.
Net margin	3.0%	Net income / revenue.
FCF margin	3.9%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	5.3%	Cash from operations / revenue.
Effective tax rate	26.1%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	11.0%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	4.7%	Net income / average total assets.
Return on invested capital (ROIC)	13.0%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	1.3%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.4%	Capital expenditures / revenue.
D&A / revenue	2.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	17.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	8.7%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	13.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	16.8%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	31.2%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	27.4%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-5.9%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	46.1%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA growth, 1y	2.1%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	40.8%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	75.8%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-15.7%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	135.3%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS growth, 1y	-15.9%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	134.4%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y	26.0%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 5y	82.8%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	16.5%	Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y	15.9%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	25.9%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	12.6%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-8.4%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	14.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	14.8%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	0.1%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.9%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	1.6%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.20x	Current assets / current liabilities.
Quick ratio	1.41x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.17x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.25x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	10.7%	Total debt / total assets.
Liabilities / assets	56.1%	Total liabilities / total assets.
Net debt	$10.6M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	0.50x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	4.39x	Operating income / interest expense.
Working capital	$56.7M	Current assets - current liabilities.
Goodwill and intangibles / assets	16.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	$46.6M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.58x	Revenue / average total assets.
Fixed asset turnover	12.6x	Revenue / average property, plant and equipment.
Inventory turnover	6.65x	Cost of revenue / average inventory.
Days inventory	55 days	365 x average inventory / cost of revenue.
Receivables turnover	4.76x	Revenue / average receivables.
Days sales outstanding	77 days	365 x average receivables / revenue.
Days payables	40 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	92 days	Days inventory + days sales outstanding - days payables.
FCF conversion	132.2%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	26.6%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$2.82	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$94.90	Revenue / diluted weighted shares.
FCF per share	$3.72	Free cash flow / diluted weighted shares.
Operating cash flow per share	$5.07	Cash from operations / diluted weighted shares.
Book value per share	$25.91	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$16.10	Tangible book value / shares outstanding.
Cash per share	$2.85	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$97.7M	Share price x shares outstanding.
Enterprise value	$108.2M	Market cap + total debt - cash - short-term investments.
P/E	11.9x	Market cap / net income. Only when net income is positive.
P/S	0.35x	Market cap / revenue.
P/B	1.30x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	2.10x	Market cap / tangible book value, when positive.
P/FCF	8.98x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	6.59x	Market cap / cash from operations, when positive.
EV/Sales	0.39x	Enterprise value / revenue.
EV/EBIT	7.19x	Enterprise value / operating income, when both are positive.
EV/EBITDA	5.06x	Enterprise value / EBITDA, when both are positive.
EV/FCF	9.95x	Enterprise value / free cash flow, when both are positive.
FCF yield	11.1%	Free cash flow / market cap.
Earnings yield	8.4%	Net income / market cap (the inverse of P/E).
PEG	0.09x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was KEWAUNEE SCIENTIFIC CORP /DE/'s revenue in fiscal 2026?

KEWAUNEE SCIENTIFIC CORP /DE/ reported revenue of $282.0M for fiscal 2026, 17.3% higher than the year before.

Was KEWAUNEE SCIENTIFIC CORP /DE/ profitable in fiscal 2026?

Yes. Net income was $9.6M, a net margin of 3.4%.

How much free cash flow did KEWAUNEE SCIENTIFIC CORP /DE/ generate in fiscal 2026?

Cash from operations of $18.6M minus capital expenditures of $3.9M left free cash flow of $14.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to KEWAUNEE SCIENTIFIC CORP /DE/